AbbVie is showcasing Vraylar at APA 2026. Here's the context, what to ask at the booth, and where Videra fits in the conversation.
Vraylar is AbbVie's flagship psychiatry brand with 4 approved indications covering the breadth of what APA attendees prescribe. Expect heavy promotion of the adjunctive MDD indication — the largest addressable market. They'll emphasize the broad label that lets one product cover multiple diagnoses a single psychiatrist manages.
Ask about: Vraylar real-world data across indications; how they position against Caplyta and Cobenfy; MDD adjunctive uptake trends; lifecycle strategy as branded generics approach; what role Vraylar plays alongside their psychedelic investment (bretisilocin). Key attendee Alex Rosen (Head of Innovation) may have different perspective than MSL team.
Vraylar RWE is the core opportunity: ePRO+ captures real-world outcomes across all 4 indications — schizophrenia speech biomarkers, bipolar mood cycling, MDD treatment response — data that periodic PANSS/MADRS visits miss. VoiceVitals enables continuous between-visit monitoring.
Position as the evidence-generation platform for formulary defense and label lifecycle. QAview relevant for any ongoing Phase 4 or HEOR studies.
Set up a follow-up with AbbVie's team and Videra Health.
Email Ryan Roberts →